Muraglitazar (Bristol-Myers Squibb/Merck).
Bristol-Myers Squibb and Merck & Co are co-developing muraglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, for the potential treatment of type 2 diabetes and other metabolic disorders. In November 2004, approval was anticipated as early as mid-2005.
Barlocco
Daniela
D
University of Milan, Istituto di Chimica Farmaceutica e Tossicologica, Viale Abruzzi 42, 20131 Milano, Italy. daniela.barlocco@unimi.it
D000818:Animals; D004345:Drug Industry / Q000379:methods / Q000639:trends; D005998:Glycine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D010080:Oxazoles / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists
D007004:Hypoglycemic Agents; D010080:Oxazoles; D047493:PPAR alpha; D047495:PPAR gamma; D005998:Glycine; C500085:muraglitazar